Sumitomo Mitsui Trust Group and Amova Asset Management's 13G/A Filing for 10x Genomics

Sumitomo Mitsui Trust Group, Inc. and Amova Asset Management Co., Ltd. have filed an amended Schedule 13G/A with the SEC, reporting their beneficial ownership of Class A common stock in 10x Genomics, Inc. The filing indicates that Sumitomo Mitsui Trust Group, Inc. and Amova Asset Management Co., Ltd. collectively own approximately 4.7% of the outstanding shares, totaling 5,381,219 and 5,376,883 shares respectively. Both entities are classified as parent holding companies and non-U.S. institutions. The securities are held in the ordinary course of business and not for the purpose of influencing control of the issuer. The filing also includes details about their subsidiaries, Amova Asset Management Americas, Inc. and Sumitomo Mitsui Trust Asset Management Co., Ltd., which are classified as investment advisers.